Resources & Guides

Semaglutide side effects guide: nausea, diarrhea, and GI symptoms from STEP and SUSTAIN trials, plus practical management tips.

Rybelsus is the semaglutide pill: the first GLP-1 receptor agonist ever approved as a swallowable tablet. This guide covers the 3, 7, and 14 mg dose ladder, the SNAC absorption enhancer that makes an oral peptide possible at all, the strict empty-stomach rules, what the tablet is and is not approved to treat, and where Rybelsus stands in 2026 as US prescriptions transition to the reformulated Ozempic pill.

There is now an oral Ozempic pill: once-daily semaglutide tablets (1.5, 4, and 9 mg) that launched in the United States on May 4, 2026. This guide covers what it is approved for, how it differs from the injectable Ozempic pen, why it is the renamed successor to Rybelsus, and why the oral option for weight loss is the separate Wegovy pill, not the Ozempic pill.

Semaglutide (Ozempic, Rybelsus) is FDA-approved for type 2 diabetes. The SUSTAIN trial programme, SUSTAIN-6 cardiovascular benefit in T2D patients, dosing, and how it differs from the weight-loss brand Wegovy.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. It's the active ingredient in Ozempic, Rybelsus, and Wegovy. This guide explains what it is, how it works, what the clinical trials show, and who qualifies for treatment.